Sector News

Hikma to split U.S. business; CEO Raya to depart

June 26, 2017
Life sciences

Hikma Pharmaceuticals PLC said Monday the chief executive of the U.S. business Michael Raya is retiring after 25 years on the job amid organizational changes at the division.

From July 1, the U.S. business will be organized into two entities–U.S. Generics Division and U.S. Injectables Division–both of which will report to the chairman and the chief executive officer of Hikma, the company said.

The company said it is doing do because it wants to “reflect its enhanced U.S. market positioning and to better align with the global Hikma organization.”

By Olga Cotaga

Source: Market Watch

Related News

October 24, 2020

Neutralising the gluten threat: are we on the cusp of a coeliac disease breakthrough?

Life sciences

Coeliac disease causes long-term damage to patients’ small intestine and puts them at risk of other medical conditions. Treatment options are urgently needed. Allie Nawrat explores the promise of larazotide, the drug in development currently leading the pack.

October 24, 2020

Bone Therapeutics showcases allogeneic cell therapy data

Life sciences

Bone Therapeutics has announced positive 24-month follow-up results from its phase IIa study of Allob, its allogeneic cell therapy, in patients undergoing lumbar spinal fusion procedures.

October 24, 2020

UCB acquires new campus to support UK operations

Life sciences

Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.

Send this to a friend